Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue 1.4 Market Analysis by Type 1.4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Corticosteroid Therapy 1.4.3 IVIG Treatment 1.4.4 Plasma Exchange Therapy 1.4.5 Immunosuppressive Drug Therapy 1.4.6 Immunomodulator Therapy 1.4.7 Other 1.5 Market by Application 1.5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2020 VS 2026 1.5.2 Hospital 1.5.3 Specialist Neurology Clinic 1.5.4 Research and Academic Laboratories 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Perspective (2015-2026) 2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Trends by Regions 2.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Share by Regions (2015-2020) 2.2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Strategy 2.3.6 Primary Interviews with Key Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Market Size 3.1.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue (2015-2020) 3.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Players (2015-2020) 3.1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio 3.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2019 3.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players Head office and Area Served 3.4 Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service 3.5 Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Type (2015-2020) 4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2021-2026) 5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Application (2015-2026) 5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) 5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020) 6.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in North America (2019-2020) 6.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) 6.4 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) 7 Europe 7.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020) 7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in Europe (2019-2020) 7.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) 7.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) 8 China 8.1 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020) 8.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in China (2019-2020) 8.3 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) 8.4 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) 9 Japan 9.1 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020) 9.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in Japan (2019-2020) 9.3 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) 9.4 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020) 10.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) 10.4 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) 11 India 11.1 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020) 11.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in India (2019-2020) 11.3 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) 11.4 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2015-2020) 12.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Players in Central & South America (2019-2020) 12.3 Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) 12.4 Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) 13Key Players Profiles 13.1 Teijin Pharma 13.1.1 Teijin Pharma Company Details 13.1.2 Teijin Pharma Business Overview and Its Total Revenue 13.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.1.4 Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020)) 13.1.5 Teijin Pharma Recent Development 13.2 Shire 13.2.1 Shire Company Details 13.2.2 Shire Business Overview and Its Total Revenue 13.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.2.4 Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.2.5 Shire Recent Development 13.3 Pfizer 13.3.1 Pfizer Company Details 13.3.2 Pfizer Business Overview and Its Total Revenue 13.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.3.4 Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.3.5 Pfizer Recent Development 13.4 Octapharma 13.4.1 Octapharma Company Details 13.4.2 Octapharma Business Overview and Its Total Revenue 13.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.4.4 Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.4.5 Octapharma Recent Development 13.5 Momenta Pharmaceuticals 13.5.1 Momenta Pharmaceuticals Company Details 13.5.2 Momenta Pharmaceuticals Business Overview and Its Total Revenue 13.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.5.4 Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.5.5 Momenta Pharmaceuticals Recent Development 13.6 Mitsubishi Tanabe Pharma Corporation 13.6.1 Mitsubishi Tanabe Pharma Corporation Company Details 13.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview and Its Total Revenue 13.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.6.4 Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.6.5 Mitsubishi Tanabe Pharma Corporation Recent Development 13.7 Kedrion 13.7.1 Kedrion Company Details 13.7.2 Kedrion Business Overview and Its Total Revenue 13.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.7.4 Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.7.5 Kedrion Recent Development 13.8 Grifols 13.8.1 Grifols Company Details 13.8.2 Grifols Business Overview and Its Total Revenue 13.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.8.4 Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.8.5 Grifols Recent Development 13.9 CSL Behring (CSL Limited) 13.9.1 CSL Behring (CSL Limited) Company Details 13.9.2 CSL Behring (CSL Limited) Business Overview and Its Total Revenue 13.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.9.4 CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.9.5 CSL Behring (CSL Limited) Recent Development 13.10 Bio Products Laboratory 13.10.1 Bio Products Laboratory Company Details 13.10.2 Bio Products Laboratory Business Overview and Its Total Revenue 13.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 13.10.4 Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 13.10.5 Bio Products Laboratory Recent Development 13.11 Baxter 10.11.1 Baxter Company Details 10.11.2 Baxter Business Overview and Its Total Revenue 10.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 10.11.4 Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 10.11.5 Baxter Recent Development 13.12 MedDay Pharmaceuticals 10.12.1 MedDay Pharmaceuticals Company Details 10.12.2 MedDay Pharmaceuticals Business Overview and Its Total Revenue 10.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 10.12.4 MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 10.12.5 MedDay Pharmaceuticals Recent Development 13.13 GeNeuro Pharmaceuticals 10.13.1 GeNeuro Pharmaceuticals Company Details 10.13.2 GeNeuro Pharmaceuticals Business Overview and Its Total Revenue 10.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction 10.13.4 GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) 10.13.5 GeNeuro Pharmaceuticals Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Key Market Segments Table 2. Key Players Covered: Ranking by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Table 3. Ranking of Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Corticosteroid Therapy Table 6. Key Players of IVIG Treatment Table 7. Key Players of Plasma Exchange Therapy Table 8. Key Players of Immunosuppressive Drug Therapy Table 9. Key Players of Immunomodulator Therapy Table 10. Key Players of Other Table 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 12. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions (US$ Million): 2020 VS 2026 Table 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Regions (2015-2020) (US$ Million) Table 14. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2015-2020) Table 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2021-2026) Table 17. Market Top Trends Table 18. Key Drivers: Impact Analysis Table 19. Key Challenges Table 20. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Strategy Table 21. Main Points Interviewed from Key Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players Table 22. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Players (2015-2020) (Million US$) Table 23. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players (2015-2020) Table 24. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2019) Table 25. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Players Market Concentration Ratio (CR5 and HHI) Table 26. Key Players Headquarters and Area Served Table 27. Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Solution and Service Table 28. Date of Enter into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Table 29. Mergers & Acquisitions, Expansion Plans Table 30. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$) Table 31. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Share by Type (2015-2020) Table 32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2021-2026) Table 33. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Share by Application (2015-2020) Table 34. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$) Table 35. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Share by Application (2021-2026) Table 36. North America Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$) Table 37. North America Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020) Table 38. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$) Table 39. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020) Table 40. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$) Table 41. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020) Table 42. Europe Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$) Table 43. Europe Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020) Table 44. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$) Table 45. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020) Table 46. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$) Table 47. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020) Table 48. China Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$) Table 49. China Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020) Table 50. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$) Table 51. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020) Table 52. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$) Table 53. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020) Table 54. Japan Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$) Table 55. Japan Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020) Table 56. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$) Table 57. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020) Table 58. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$) Table 59. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020) Table 60. Southeast Asia Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$) Table 61. Southeast Asia Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020) Table 62. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$) Table 63. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020) Table 64. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$) Table 65. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020) Table 66. India Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$) Table 67. India Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020) Table 68. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$) Table 69. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020) Table 70. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$) Table 71. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020) Table 72. Central & South America Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (2019-2020) (Million US$) Table 73. Central & South America Key Players Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share (2019-2020) Table 74. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2015-2020) (Million US$) Table 75. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type (2015-2020) Table 76. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2015-2020) (Million US$) Table 77. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application (2015-2020) Table 78. Teijin Pharma Company Details Table 79. Teijin Pharma Business Overview Table 80. Teijin Pharma Product Table 81. Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 82. Teijin Pharma Recent Development Table 83. Shire Company Details Table 84. Shire Business Overview Table 85. Shire Product Table 86. Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 87. Shire Recent Development Table 88. Pfizer Company Details Table 89. Pfizer Business Overview Table 90. Pfizer Product Table 91. Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 92. Pfizer Recent Development Table 93. Octapharma Company Details Table 94. Octapharma Business Overview Table 95. Octapharma Product Table 96. Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 97. Octapharma Recent Development Table 98. Momenta Pharmaceuticals Company Details Table 99. Momenta Pharmaceuticals Business Overview Table 100. Momenta Pharmaceuticals Product Table 101. Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 102. Momenta Pharmaceuticals Recent Development Table 103. Mitsubishi Tanabe Pharma Corporation Company Details Table 104. Mitsubishi Tanabe Pharma Corporation Business Overview Table 105. Mitsubishi Tanabe Pharma Corporation Product Table 106. Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 107. Mitsubishi Tanabe Pharma Corporation Recent Development Table 108. Kedrion Company Details Table 109. Kedrion Business Overview Table 110. Kedrion Product Table 111. Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 112. Kedrion Recent Development Table 113. Grifols Business Overview Table 114. Grifols Product Table 115. Grifols Company Details Table 116. Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 117. Grifols Recent Development Table 118. CSL Behring (CSL Limited) Company Details Table 119. CSL Behring (CSL Limited) Business Overview Table 120. CSL Behring (CSL Limited) Product Table 121. CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 122. CSL Behring (CSL Limited) Recent Development Table 123. Bio Products Laboratory Company Details Table 124. Bio Products Laboratory Business Overview Table 125. Bio Products Laboratory Product Table 126. Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 127. Bio Products Laboratory Recent Development Table 128. Baxter Company Details Table 129. Baxter Business Overview Table 130. Baxter Product Table 131. Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 132. Baxter Recent Development Table 133. MedDay Pharmaceuticals Company Details Table 134. MedDay Pharmaceuticals Business Overview Table 135. MedDay Pharmaceuticals Product Table 136. MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 137. MedDay Pharmaceuticals Recent Development Table 138. GeNeuro Pharmaceuticals Company Details Table 139. GeNeuro Pharmaceuticals Business Overview Table 140. GeNeuro Pharmaceuticals Product Table 141. GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) (Million US$) Table 142. GeNeuro Pharmaceuticals Recent Development Table 143. Research Programs/Design for This Report Table 144. Key Data Information from Secondary Sources Table 145. Key Data Information from Primary Sources List of Figures Figure 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type: 2020 VS 2026 Figure 2. Corticosteroid Therapy Features Figure 3. IVIG Treatment Features Figure 4. Plasma Exchange Therapy Features Figure 5. Immunosuppressive Drug Therapy Features Figure 6. Immunomodulator Therapy Features Figure 7. Other Features Figure 8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2020 VS 2026 Figure 9. Hospital Case Studies Figure 10. Specialist Neurology Clinic Case Studies Figure 11. Research and Academic Laboratories Case Studies Figure 12. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Years Considered Figure 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth 2015-2026 (US$ Million) Figure 14. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions: 2020 VS 2026 Figure 15. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Regions (2021-2026) Figure 16. Porter's Five Forces Analysis Figure 17. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players in 2019 Figure 18. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2019 Figure 19. The Top 10 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2019 Figure 20. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$) Figure 22. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$) Figure 25. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$) Figure 26. Central & South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2015-2020) (Million US$) Figure 27. Teijin Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. Teijin Pharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 29. Shire Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Shire Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 31. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Pfizer Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 33. Octapharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Octapharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 35. Momenta Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. Momenta Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 37. Mitsubishi Tanabe Pharma Corporation Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Mitsubishi Tanabe Pharma Corporation Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 39. Kedrion Total Revenue (US$ Million): 2019 Compared with 2018 Figure 40. Kedrion Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 41. Grifols Total Revenue (US$ Million): 2019 Compared with 2018 Figure 42. Grifols Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 43. CSL Behring (CSL Limited) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 44. CSL Behring (CSL Limited) Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 45. Bio Products Laboratory Total Revenue (US$ Million): 2019 Compared with 2018 Figure 46. Bio Products Laboratory Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 47. Baxter Total Revenue (US$ Million): 2019 Compared with 2018 Figure 48. Baxter Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 49. MedDay Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 50. MedDay Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 51. GeNeuro Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 52. GeNeuro Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2015-2020) Figure 53. Bottom-up and Top-down Approaches for This Report Figure 54. Data Triangulation Figure 55. Key Executives Interviewed

Teijin Pharma Shire Pfizer Octapharma Momenta Pharmaceuticals Mitsubishi Tanabe Pharma Corporation Kedrion Grifols CSL Behring (CSL Limited) Bio Products Laboratory Baxter MedDay Pharmaceuticals GeNeuro Pharmaceuticals